A Safety and Efficacy Study of Mycophenolate Mofetil and Rilonacept in Patients With Alcoholic Hepatitis

Inclusion Criteria: * History of chronic alcohol consumption (defined as \>60g ethanol/day for women and \>80g ethanol/day for men) for at least the past 5 years * Less than 8 weeks between last intake of alcohol and Screening * Maddrey's Discriminant Function score (DF)\>32 * Willing to undergo liver biopsy for histological assessment of alcoholic hepatitis. * Willing to provide liver tissue, whole blood, stool and ascitic fluid as part of a correlative study * Onset of jaundice \<3 months prior to Screening * Age greater or equal to 18 years Exclusion Criteria (Brief): * Liver disease significantly caused by etiologies other than alcohol. * Upper GI bleeding requiring transfusion within 48 hours prior to start of prednisolone (Day 1) * Infection that has been treated with appropriate antibiotics for less than 72 hours or which has not responded appropriately to 72 hours or more of antibiotic treatment prior to start of prednisolone (Day 1) * Clinical evidence of select active infections in the past 3 months (fungal, mycobacterial, cytomegalovirus (CMV), herpes, coccidioidomycosis, tuberculosis (TB) and human immunodeficiency virus (HIV)) * Renal insufficiency * Laboratory exclusions * Hemoglobin \<7g/dL * Total Bilirubin \<7.5mg/dL * Aspartate aminotransferase (AST) \>500 IU/mL; or AST:Alanine aminotransferase (ALT) ratio \< 1 * Pregnant or breast-feeding or unwilling to use appropriate birth control * Other clinically significant diseases (uncontrolled diabetes, severe …